KMT2A and acute lymphoblastic leukemia: We therefore proceeded to assess whether inhibition of the BCL-2 anti-apoptotic pathway overcomes resistance to RK-20449/dexamethasone combination treatment, using MLL-ALL cells that survived dexamethasone/RK-20449 combination treatment (Patients 4, 6 and 11) (See Table S2).